Benefits of histone deacetylase inhibitors for acute brain injury: A systematic review of animal studies

Journal of Neurochemistry

Volumn 115, Issue 4, 2010, Pages 806-813

  Gibson, Claire L ^a   Murphy, Sean P ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CNS injury; Histone deacetylase; Mouse; Rat; Systematic review

Indexed keywords

4 DIMETHYLAMINO N [5 (2 MERCAPTOACETYLAMINO)PENTYL]BENZAMIDE; 4 PHENYLBUTYRIC ACID; BUTYRIC ACID; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

BRAIN INJURY; BRAIN ISCHEMIA; DRUG EFFICACY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE;

ANIMALS; BRAIN INJURIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HUMANS;

ANIMALIA; RATTUS;

EID: 77958544846     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06993.x     Document Type: Review

References (41)

1. Baltan S., Murphy S. P., Danilov C. A., Bachleda A. and Morrison R. S. (2010) Class I histone deacetylase inhibition preserves glial cell function and viability to protect white matter from ischemic injury. Program No. 345.4. 2010 Neuroscience Meeting Planner. Society for Neuroscience, San Diego, CA. Online.
2. Bath P. M. W., Gray L. J., Buchan A., Miyata T. and Green A. R. (2009) Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br. J. Pharmacol. 157, 1157-1171.
3. Chuang D. M., Leng Y., Marinova Z., Kim H. J. and Chiu C. T. (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591-601.
4. Crossley N. A., Sena E., Goehler J., Horn J., Van Der Worp B., Bath P. M. W., Macleod M. and Dirnagl U. (2008) Empirical evidence of bias in the design of experimental stroke studies. Stroke 39, 929-934.
5. Dash P. K., Orsi S. A. and Moore A. N. (2009) Histone deacetylase inhibition combined with behavioural therapy enhances learning and memory following traumatic brain injury. Neuroscience 163, 1-8.
6. DerSimonian R. and Laird N. (1986) Meta analysis in clinical trials. Control. Clin. Trials 7, 177-178.
7. Egger M., Davey Smith G., Schneider M. and Minder C. (1997) Bias in 600 meta-analyses detected by a simple graphical test. Br. Med. J. 315, 629-634.
8. England T. J., Gibson C. L. and Bath P. M. W. (2009) Granulocyte-colony stimulating factor in experimental stroke and its effect on infarct size and functional outcome: a systematic review. Brain Res. Rev. 62, 71-82.
9. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., Moroni F. and Chiarugi A. (2006) Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxyamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70, 1876-1884.
10. Gibson C. L., Gray L. J., Murphy S. P. and Bath P. M. W. (2006) Estrogens and experimental ischemic stroke: a systematic review. J. Cereb. Blood Flow Metab. 26, 1103-1113.
11. Gibson C. L., Gray L. J., Bath P. M. W. and Murphy S. P. (2008) Progesterone for the treatment of experimental brain injury; a systematic review. Brain 131, 318-328.
12. Guan J.-S., Haggarty S. J., Giacometti E. et al. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60.
13. Haberland M., Montgomery R. L. and Olson E. N. (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32-42.
14. Kabakus N., Ay I., Aysun S., Soylemezoglu F., Ozcan A. and Celasun B. (2005) Protective effects of valproic acid against hypoxic-ischemic brain injury in neonatal rats. J. Child Neurol. 20, 582-587.
15. Kilkenny C., Parsons N., Kadyszewski E., Festing M. F. W., Cuthill I. C., Fry D., Hutton J. and Altman D. G. (2009) Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS ONE 4, e7824.
16. Kilkenny C., Browne W., Cuthill I. C., Emerson M. and Altman D. G. (2010) Improving bioscience research reporting - ARRIVE-ing at a solution. PLoS Biol. 8, e1000412.
17. Kim H. J., Rowe M., Ren M., Hong J.-S., Chen P.-S. and Chuang D.-M. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321, 892-901.
18. Kim H. J., Leeds P. and Chuang M.-W. (2009) The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem. 110, 1226-1240.
19. Kim J. Y., Shen S., Dietz K., He Y., Howell O., Reynolds R. and Casaccia P. (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13, 180-189.
20. Kramer O. H. (2009) HDAC2: a critical factor in health and disease. Trends Pharmacol. Sci. 30, 647-655.
21. waf1/cip1 in cell cycle-independent neuroprotection. J. Neurosci. 28, 163-176.
22. Langley B., Brochier C. and Rivieccio M. A. (2009) Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke. Stroke 40, 2899-2905.
23. Lee S. and Lee S.-K. (2010) Crucial roles of histone-modifying enzymes in mediating neural cell-type specification. Curr. Opin. Neurobiol. 20, 29-36.
24. Macleod M. R., O'Collins T., Horky L. L., Howells D. W. and Donnan G. A. (2005) Systematic review and meta-analysis of the efficacy of FK506 in experimental stroke. J. Cereb. Blood Flow Metab. 25, 713-721.
25. Marks P. A. and Xu W.-S. (2009) Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107, 600-608.
26. Minucci S. and Pelicci P. G. (2006) HDAC inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51.
27. Montgomery R. L., Hsieh J., Barbosa A. C., Richardson J. A. and Olson E. N. (2009) HDACs 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl Acad. Sci. USA 106, 7876-7881.
28. Philip M., Benatar M., Fisher M. and Savitz S. I. (2009) Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 40, 577-581.
29. Prince H. M., Bishton M. J. and Harrison S. J. (2009) Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 15, 3958-3969.
30. Qi X., Hosoi T., Okuma Y., Kaneko M. and Nomura Y. (2004) Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66, 899-908.
31. Ren M., Leng Y., Jeong M., Leeds P. R. and Chuang M.-W. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89, 1358-1367.
32. Rivieccio M. A., Brochier C., Willis D. E. et al. (2009) HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc. Natl Acad. Sci. USA 106, 19599-19604.
33. Ryu H., Lee J., Olofsson B. A. et al. (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an sp1-dependent pathway. Proc. Natl Acad. Sci. USA 100, 4281-4286.
34. Sena E. S., Van Der Worp H. B., Bath P. M. W., Howells D. W. and Macleod M. R. (2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 8, e1000344.
35. Shein N. A., Grigoriadis N., Alexandrovich A. G. et al. (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23, 4266-4275.
36. Sinn D.-I., Kim S.-J., Chu K. et al. (2007) Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 26, 464-472.
37. Sweatt J. D. (2009) Experience-dependent epigenetic modifications in the CNS. Biol. Psychiatry 65, 191-197.
38. Thomas E. A. (2009) Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol. Neurobiol. 40, 33-45.
39. Uo T., Veenstra T. D. and Morrison R. S. (2009) HDAC inhibitors prevent p53-dependent and -independent Bax-mediate neuronal apoptosis through two distinct mechanisms. J. Neurosci. 29, 2824-2832.
40. Yildrim F., Gertz K., Kronenberg G., Harms C., Fink K. B., Meisel A. and Endres M. (2008) Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol. 210, 531-542.
41. Zhang B., West E., Van K. C., Gurkoff G. G., Zhou J., Zhang X.-M., Kozikowski A. P. and Lyeth B. G. (2008) HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res. 1226, 181-191.